Med-IQ

04/07/2026

: Is your EHR strengthening team communication?
Seamless information exchange prevents errors and improves patient outcomes. Regularly reviewing your system’s capabilities can reduce EHR-related malpractice risk.

This week’s tips:
🔹Check that your EHR supports efficient communication among care teams
🔹Ensure the ability to document telephone calls and nontraditional patient encounters
🔹Provide additional training for all users, even if staff members have been using the system for years

Med-IQ is introducing budget-conscious options for risk management and patient safety programs. Our goal is to help you deliver high-quality, engaging, actionable learning without draining your team's time or resources.

Whether you’re reducing liability risk, improving outcomes, or strengthening safety culture, our tailored solutions make it easier—and more affordable—to achieve your goals.

Let’s talk about your priorities. Email Contact@med-iq.com or visit https://info.med-iq.com/.../a/31318/p/p-0023/t/page/fm/0

03/31/2026

: The Power of Reminders in Your EHR

A surprising number of EHR-related medical malpractice claims can be avoided by simply reviewing your system’s capabilities. This special covers actionable steps to help safeguard your practice.

Use Your EHR's Reminder System.

Make sure your EHR allows healthcare professionals and staff to set reminders for crucial actions, such as:
▪️Follow-up labs
▪️Routine testing
▪️Issues to address in future visits

Using reminders helps ensure that nothing slips through the cracks, reducing clinical risks and protecting patients.

Med-IQ is introducing budget-conscious options for risk management and patient safety programs. Our goal is to help you deliver high-quality, engaging, actionable learning without draining your team's time or resources.

Whether you’re reducing liability risk, improving outcomes, or strengthening safety culture, our tailored solutions make it easier—and more affordable—to achieve your goals.

Let’s talk about your priorities. Email Contact@med-iq.com or visit https://info.med-iq.com/.../a/31318/p/p-0023/t/page/fm/0

03/30/2026

CME Opportunity: Evolving Treatment Strategies in ATTR-CM
Transthyretin amyloid cardiomyopathy (ATTR-CM) is no longer the “rare, untreatable” disease it once was. With multiple FDA-approved therapies—and several more in latephase trials—the treatment landscape is changing fast.

In this free activity, expert faculty breaks down:
- How tafamidis, acoramidis, and vutrisiran differ—and where each fits
- What and updates mean for practice
- How to incorporate emerging silencers, antibodies, and gene editing candidates
- Why early, accurate diagnosis matters more than ever

Earn CME credit: http://miq-clinical.med-iq.com/activity/attr-cm-treatment-changing-the-paradigm

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

03/30/2026

On March 30, National Doctors’ Day, we are taking a moment to recognize physicians with the dignity the profession deserves. We see your resilience and dedication, and, in return, we dedicate ourselves further to providing you with high-quality, engaging CME tailored to your professional needs.

03/28/2026

Hypertrophic cardiomyopathy ( ) management is evolving fast. This CME accredited course gives you the latest diagnostic strategies, echo essentials, and updates on mavacamten and aficamten.
Stay ahead of the curve—improve outcomes for patients with HCM and oHCM.
Update Your HCM Expertise: https://clinical.med-iq.com/activity/ohcm-changing-the-paradigm-for-clinicians-and-keeping-patients-informed?utm_source=fb&utm_medium=social&utm_campaign=BM194-fb

03/25/2026

This focused offering will arm you with the targeted insights and tools you need to identify “red flags,” ask the right questions, and empower patients and caregivers. http://miq-clinical.med-iq.com/activity/hcm-red-flags-what-clinicians-need-to-know
Navigate Complexity ⇒ Learn how to avoid common pitfalls and dig deeper with patients to prevent missed or delayed HCM diagnoses.
Update Practice ⇒ Review the most current management guidelines, including the introduction of the cardiac myosin inhibitor mavacamten for obstructive HCM.
Integrate the Latest Evidence ⇒ The 2024 HCM guideline updates reflect major advances. This course simplifies the key evidence and helps you translate new recommendations into everyday care.

In this accredited CME activity, internationally recognized hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez navigates the complexities of diagnosing HCM and explains when to dig deeper with patients to avoid misdiagnoses. He reviews guidelines for the management of HCM and provides pra...

03/24/2026

: Clear communication between providers is one of the most powerful ways to safeguard patients. From creating clear communication plans to using closed-loop techniques, simple steps can reduce errors and strengthen coordination.

Med-IQ is introducing budget-conscious options for risk management and patient safety programs. Our goal is to help you deliver high-quality, engaging, actionable learning without draining your team's time or resources.

Whether you’re reducing liability risk, improving outcomes, or strengthening safety culture, our tailored solutions make it easier—and more affordable—to achieve your goals.

Let’s talk about your priorities. Email Contact@med-iq.com or visit https://info.med-iq.com/acton/fs/blocks/showLandingPage/a/31318/p/p-0023/t/page/fm/0

03/20/2026

Transthyretin amyloid cardiomyopathy (ATTR-CM) often hides in plain sight. In this American College of Cardiology CardiaCast, Michelle Kittleson, MD, PhD, and Jan Griffin, MD, FACC, team up to help clinicians spot it sooner and manage it better.

In this episode, they break down:
- Subtle cardiac and extracardiac clues that raise suspicion
- A practical diagnostic pathway
- Screening strategies for at risk patients
- Current disease modifying treatments and heart failure management pearls
- Tips for ongoing monitoring and identifying treatment candidates
-Promising future therapies

🎧 Tune in to level up your ATTR-CM expertise!

03/19/2026

Happy Certified Nurses Day!
THANK YOU for your dedication to nursing excellence and your work to become an expert in your specialty area! Your efforts are noticed and greatly appreciated. You make an important difference, serve as role models, and routinely help ensure safe, high quality patient care.

03/19/2026

Welcome to the team, Piper Probst, DNP, MSN, RN, NEA-BC, NPD-BC!

We’re excited to welcome Dr. Probst as our new Senior Director, Medical Education and Risk Consulting. She brings more than 30 years of healthcare experience across operations, education, and administrative leadership. Dr. Probst holds a Doctor of Nursing Practice and a Master of Science in Nursing. She also holds two board certifications: Nurse Executive-Advanced and Nursing Professional Development.

Dr. Probst’s background includes experience in inpatient and outpatient settings, more than 15 years in healthcare education and leadership development, and a strong servant leadership philosophy. She is also a Six Sigma Black Belt, an MBTI® Qualified Facilitator, and has extensive experience collaborating across complex health systems.

We’re thrilled to have her expertise and leadership at Med-IQ. Please join us in welcoming Dr. Probst to the team!

03/17/2026

: A gracious exit builds trust, ensures clarity, and minimizes communication gaps. At every visit’s end, wrap up by ensuring patients feel informed and cared for.

Med-IQ is introducing budget-conscious options for risk management and patient safety programs. Our goal is to help you deliver high-quality, engaging, actionable learning without draining your team's time or resources.

Whether you’re reducing liability risk, improving outcomes, or strengthening safety culture, our tailored solutions make it easier—and more affordable—to achieve your goals.

Let’s talk about your priorities. Email Contact@med-iq.com or visit https://info.med-iq.com/acton/fs/blocks/showLandingPage/a/31318/p/p-0023/t/page/fm/0

03/16/2026

Expert faculty discuss the latest clinical study data for several investigational therapies for recurrent/metastatic head and neck squamous cell carcinoma, with an emphasis on trial results presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium.